menu
    • menu
    [{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Vormatrigine","moa":"Voltage-gated sodium channels","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Praxis Precision Medicines \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Piper Sandler | TD Cowen | Guggenheim Securities | Truist Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2026","type":"Public Offering","leadProduct":"Vormatrigine","moa":"Voltage-gated sodium channel","graph1":"Neurology","graph2":"Phase III","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Praxis Precision Medicines \/ Piper Sandler | TD Cowen | Guggenheim Securities | Truist Securities","highestDevelopmentStatusID":"10","companyTruncated":"Praxis Precision Medicines \/ Piper Sandler | TD Cowen | Guggenheim Securities | Truist Securities"}]

    Find Clinical Drug Pipeline Developments & Deals for Vormatrigine

    Menu

    Vormatrigine

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Praxis Precision Medicines

                            U.S.A arrow
                            Pharmapack
                            Not Confirmed

                            Praxis Precision Medicines

                            U.S.A arrow
                            Pharmapack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vormatrigine

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Piper Sandler | TD Cowen | Guggenheim Securities | Truist Securities

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Praxis Precision Medicines Announces Public Offering

                            Details : The proceeds from the offering will be used to fund the clinical development of Vormatrigine, a novel treatment targeting voltage-gated sodium channels for epilepsy, specifically Tonic-Clonic seizures.

                            Product Name : PRAX-628

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            January 06, 2026

                            Lead Product(s) : Vormatrigine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Piper Sandler | TD Cowen | Guggenheim Securities | Truist Securities

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Praxis Precision Medicines

                            U.S.A arrow
                            Pharmapack
                            Not Confirmed

                            Praxis Precision Medicines

                            U.S.A arrow
                            Pharmapack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vormatrigine

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Trial of Vormatrigine in Adult Patients With Epilepsy

                            Details : PRAX-628 (Vormatrigine) is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Epilepsy, Tonic-Clonic.

                            Product Name : PRAX-628

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 17, 2025

                            Lead Product(s) : Vormatrigine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.